Meissa is involved in the manufacturing and sale of hospital equipment and furniture, focusing on medical products such as hospital beds, medical tables, and various hospital supplies. The company emphasizes quality and functionality in its offerings.

Meissa

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Kyung Ae Lee

Thomas A Wynn

Christina Warren

Pfizer Inc.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Jean-René Sautier

Jean-François Dehecq

Sanofi

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

John Smith

Nicholas Babaian

GSK plc

Meissa manufactures and sells hospital equipment and furniture. The company has been committed to R&D activities and has invested significantly in this area, achieving success in exporting its products to many countries.

Meissa Medical Devices | 340 followers on LinkedIn. Provide Healty Solutions | MEYSA TIBBİ CİHAZLAR SAN VE TİC. A.Ş.  “MEISSA” markası altında hasta yatağı, yoğun bakım karyolası, sedye ve hasta odası ekipmanları üretimi, gelişimi ve alternatif çözümler sağlama konusunda sektöre hizmet vermektedir.

Meissa Medical Devices şirketinde Export Sales

Yusuf Özgün

Mustafa Sağlamkendirgil

Biomedical Engineer

Mustafa Peker

Digital Marketing Manager - Meissa Medical Devices

Meysa Tıbbi

Meissa Medical Devices

You are welcome to visit our booth at the Medica trade fair. Hall - 12 Stand - C60

Ankara Ticaret Odası (ATO) başkanımız Sn. Gürsel Baran’ı ziyaret ederek hasbihal ettik.

Sayın Kayseri Valimiz Gökmen Çiçeği Makamında Ziyaret Ettik. Bayram Karaman

Furkan Ozsoy

Sevdiklerinizle bir arada olduğunuz, mutlu ve sağlıklı bir bayram dileriz. Kurban Bayramınız kutlu olsun!

Meysa A.Ş. olarak Galatasarayımızın 2023/2024 sezonu süper lig şampiyonluğunu tebrik ederiz.

New gynegolocigal exhamination couch from Meissa #meissa #hospitalbed #hospitalequipment

We are working to be better #meissa #medicalequipment #hospitalbed #stretcher #hospital

19 Mayıs Gençlik Ve Spor Bayramı Kutlu Olsun 👏🏻

Metric
Company Name	Meissa	Pfizer Inc.	Sanofi	GSK plc
Symbol		PFE	SAN	GSK
MSH ID	TR:COM:MEISSA	COM:PFIZER	COM:SANOFI	COM:GSK
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Medical Equipment Manufacturing	Drug Manufacturers - General	Drug Manufacturers - General	Drug Manufacturers - General
Country	TR	US	FR	GB
Stage
Employee Count		88K	86.09K	70.21K
Website	meissa.com.tr	pfizer.com	sanofi.com	gsk.com
LinkedIn	meissa-medical-devices	pfizer	sanofi
Founders

Metric
Market Cap		160.65B	125.22B	786.32M
Enterprise Value
Monthly Web Traffic	2.42K	1.84M	1.77M	1.33M
Web Traffic Growth	0.44	0.15	1.26	0.02
Valuation
Raised Capital		1B	329.02M

Metric
Revenue	58.50B	45.49B	38.64B
Revenue (LTM)
Revenue (NTM)
Gross Profit	29.28B	27.99B	27.08B
EBITDA	10.53B	13.69B	11.83B
Operating Income	4.24B	9.70B	8.91B
Net Income	2.12B	5.70B	6.28B
EPS	0.38	4.55	1.55
Diluted EPS	0.38	4.54	1.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.52	0.68	0.73
Operating Profit Margin	0.06	0.26	0.26
EBITDA Margin	0.18	0.30	0.31
Net Profit Margin	0.04	0.14	0.16
Return on Equity	0.02	0.11	0.39
Return on Assets	0.01	0.06	0.08
Return on Capital Employed	5.56	0.15	0.20

COM

TR:COM:MEISSA

Meissa

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	14.35	12.01	11.10
P/B Ratio	1.55	1.51	5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.21	2.28	2.37
EV Multiple	17.74	7.47	5.83

Metric
Days Sales Outstanding	79.90	2.82
Days Payables Outstanding	72.06	505.63	678.29
Days Inventory Outstanding	155.46	205.19	247.86
Operating Cycle	230.19	262.40	338.14
Cash Conversion Cycle	160.85	116.95	-264.26
Asset Turnover	141.27	0.52	0.54

Metric
Operating Cash Flow	8.70B	10.83B	8.09B
Free Cash Flow	4.79B	7.40B	5.10B
Cash Flow to Debt	0.12	0.62	0.42
Operating Cash Flow/Sales	0.16	0.18	0.24
Free Cash Flow Yield	0.05		0.05

Metric
Cash & Equivalents	2.85B	9.20B	3.74B
Accounts Receivable	347M	-419.32M	-826.97M
Inventory	10.19B	10.21B	7.01B
Goodwill	67.78B	52.18B	8.68B
Debt to Capitalization	0.45	0.23	0.56
Debt to Assets	0.30	0.17	0.34
Current Ratio	2.38	1.22	0.95
Quick Ratio	94.70	0.83	0.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.17	0.15	0.20
SG&A to Revenue			0.31